Crinetics Pharmaceuticals Inc (CRNX)vsMerck & Company Inc (MRK)
CRNX
Crinetics Pharmaceuticals Inc
$84.95
0.00%
HEALTHCARE · Cap: $9.01B
MRK
Merck & Company Inc
$144.85
+0.64%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 157811% more annual revenue ($66.57B vs $42.16M). MRK leads profitability with a 4.8% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 36/100 (F).
CRNX
Avoid32
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+87.2%
Fair Value
$370.52
Current Price
$84.95
$285.57 discount
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$144.85
$62.01 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 2336.0% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -38.8% — below average capital efficiency
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : CRNX
The strongest argument for CRNX centers on Revenue Growth, Debt/Equity. Revenue growth of 2336.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : CRNX
The primary concerns for CRNX are EPS Growth, Profit Margin, Piotroski F-Score.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
CRNX profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.23 — expect wider price swings.
CRNX is growing revenue faster at 2336.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 32/100). CRNX offers better value entry with a 87.2% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Crinetics Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?